EORTC: Working towards “Closing the Care Gap”
2 Feb 2023
Brussels, 2 February 2023: The European Organisation for Research and Treatment of Cancer (EORTC) is proud to support World Cancer Day 2023, held every year on 4 February. This is an important moment to join forces with the Union for International Cancer Control (UICC), its members, partners, supporters and everyone around the world to raise awareness about the importance of ensuring that access to cancer treatment and care is equitable for all patients, whoever and wherever they are.
On this occasion, the EORTC is proud to release a new video presenting the tremendous work of our organisation and dedicated Quality of Life Group in helping “Close the Care Gap”.
Today, half of the global population still lacks access to the full range of essential health services, including accurate information and quality care services in prevention, diagnosis, treatment and support.
In fact, in every part of the world, people who seek cancer treatment and care hit barriers such as income, race gender, sexual orientation and age. For example, 70% of cancer deaths – and more than 90% of cervical cancer mortality – occur in low-to-middle-income countries. Furthermore, while over 370 million indigenous people live across at least 70 countries worldwide, like other minority populations, due to racism, they often face serious barriers in accessing their countries’ basic health services, and, in turn, poorer outcomes.1
How does the EORTC help “Close the Care Gap”
The EORTC has a long history of improving cancer treatment and care for all patients globally. Through dedicated clinical research and expansion in further regions of the world, the EORTC is committed to maintaining therapeutic progress for all. The EORTC is also actively working to “Close the Care Gap” by delivering important datasets to optimise cancer treatments and move forward with a truly patient-centric approach.
Through the development of questionnaires to assess health-related quality of life of cancer patients, including for rare cancers, the EORTC Quality of Life Group strives to give them a voice, putting their experiences at the forefront and exploring the barriers that stand in their way of cancer care.
Prof. Eva Greimel, Clinical and Health Psychologist, Department of Gynecology, Medical University Graz (Austria), recalls that, “The first Quality of Life questionnaire for women with ovarian cancer was developed 20 years ago. Since the majority of these patients are diagnosed with advanced disease, quality of life is a critical treatment aspect to measure. The ovarian cancer module has been used in many clinical trials, so we have given these women a voice.”
The EORTC will continue to aim to increase cancer survival, but also to improve quality of life of cancer patients, as well as cancer survivors.
Watch our video above and get ready to engage on World Cancer Day, including by sharing this on social media and using #GivingVoice2Patients, #WorldCancerDay and #CloseTheCareGap! Together, let’s “Close the Care Gap”!
About EORTC
The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.
About the Quality of Life Group
The Quality of Life Group (QLG) strives to improve health-related quality of life (HRQoL) of cancer patients, through dedicated research and the use of HRQoL measures within cancer clinical trials and clinical practice. HRQoL constitutes an important aspect of cancer research and care: it gives a voice to patients, putting their experience at the forefront. The QLG is part of the European Organisation for Research and Treatment of Cancer (EORTC).
For further information, please visit the QLG website.
Contact
Caroline Hance (EORTC QLG)
Strategic Lead Communication
caroline.hance@eortc.org
Related News
EORTC strategic meeting with Middle Eastern Ambassadors
26 Sep 2023
EORTC Quality of Life Group projects to be presented at ISOQOL 2023
22 Sep 2023
Celebrating Sarcoma Awareness Month with the start of EU-funded STREXIT 2 project study
17 Jul 2023
“Best Proposal in Medicine” award received by EORTC at the PTCOG 61 Conference
30 Jun 2023
Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma
16 Jun 2023
Joint Statement: health organisations define EHDS’ opt out required for life saving research
9 Jun 2023
Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award
7 Jun 2023
Full validation of the EORTC CAT Core
6 Jun 2023
SISAQOL-IMI: Setting standards for the use of patient-reported outcome data in cancer trials
1 Jun 2023
Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types
30 May 2023